News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
303 Results
Type
Article (45)
Company Profile (1)
Press Release (257)
Section
Business (116)
Deals (16)
Drug Development (37)
FDA (1)
Job Trends (26)
News (147)
Policy (2)
Tag
Alliances (18)
Alzheimer's disease (1)
Approvals (3)
Artificial intelligence (1)
Best Places to Work (23)
Brain cancer (1)
Breast cancer (20)
Cancer (32)
CDC (1)
Clinical research (32)
Collaboration (2)
COVID-19 (2)
C-suite (3)
Cystic fibrosis (1)
Data (20)
Diagnostics (1)
Earnings (49)
Events (82)
Executive appointments (3)
FDA (9)
Funding (1)
Government (2)
Guidances (3)
Healthcare (5)
Immunology and inflammation (1)
Infectious disease (2)
IPO (12)
Job creations (1)
Layoffs (1)
Lung cancer (1)
Lymphoma (5)
Medical device (1)
Medtech (1)
Mergers & acquisitions (4)
Metabolic disorders (1)
Neurodegenerative disease (2)
Neuroscience (6)
NextGen: Class of 2026 (4)
Now hiring (2)
Obesity (1)
Parkinson's disease (6)
Patient recruitment (1)
People (62)
Pharmaceutical (1)
Phase 1 (20)
Phase 2 (12)
Phase 3 (8)
Pipeline (6)
Policy (1)
Preclinical (14)
Prostate cancer (3)
Radiopharmaceuticals (1)
Rare diseases (2)
Regulatory (6)
Series B (1)
Startups (11)
The Weekly (1)
Vaccines (1)
Venture capital (1)
Date
Today (1)
Last 7 days (4)
Last 30 days (5)
Last 365 days (44)
2026 (15)
2025 (49)
2024 (44)
2023 (35)
2022 (34)
2021 (33)
2020 (31)
2019 (21)
2018 (12)
2017 (9)
2016 (8)
2015 (7)
2014 (4)
2013 (1)
Location
Asia (1)
California (3)
Canada (1)
Colorado (1)
Connecticut (55)
Europe (13)
Illinois (1)
Indiana (2)
Massachusetts (6)
New Jersey (1)
New York (11)
North Carolina (1)
Northern California (2)
Pennsylvania (2)
Rhode Island (1)
Texas (1)
United States (74)
303 Results for "arvinas".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026
May 5, 2026
·
1 min read
Approvals
FDA clears Pfizer, Arvinas’ novel breast cancer therapy despite mixed data
Veppanu, the first PROTAC therapy approved by the FDA, improved progression free survival by 43% versus AstraZeneca’s Faslodex but showed no such significant benefit in the intention-to-treat analysis.
May 4, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Arvinas to Participate in Upcoming March 2026 Investor Conferences
February 23, 2026
·
1 min read
Press Releases
Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
May 3, 2026
·
13 min read
Press Releases
Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
February 24, 2026
·
28 min read
Press Releases
Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
February 17, 2026
·
1 min read
Press Releases
Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director
February 12, 2026
·
7 min read
Press Releases
Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer’s VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations
May 4, 2026
·
4 min read
Press Releases
Arvinas to Participate in Upcoming November 2025 Investor Conferences
November 4, 2025
·
1 min read
Press Releases
Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days
March 18, 2026
·
10 min read
1 of 31
Next
